[{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm \/ Not Applicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"BBIBP-CorV","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Sinopharm \/ Not Applicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"G42 Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ G42 Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm \/ G42 Healthcare"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm \/ Not Applicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm \/ Not Applicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sinopharm \/ Not Applicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinopharm \/ Shanghai Fosun Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Sinopharm \/ Shanghai Fosun Pharma"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinopharm \/ Not Applicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Beijing Institute of Biological Product","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Beijing Institute of Biological Product","highestDevelopmentStatusID":"12","companyTruncated":"Sinopharm \/ Beijing Institute of Biological Product"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Inactivated Covid-19 vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinopharm \/ Not Applicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Inactivated SARS-CoV-2 vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sinopharm \/ Not Applicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Brii Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Amubarvimab","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Sinopharm","highestDevelopmentStatusID":"12","companyTruncated":"Sinopharm \/ Sinopharm"},{"orgOrder":0,"company":"Sinopharm","sponsor":"ChromaDex, Inc","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Nicotinamide Riboside","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Approved","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sinopharm \/ ChromaDex","highestDevelopmentStatusID":"12","companyTruncated":"Sinopharm \/ ChromaDex"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"mRNA-based COVID-19 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sinopharm \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"Sinopharm \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Sinopharm

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Sinopharm's mRNA-based COVID-19 vaccine was developed using the traditional method, by means of an inactivated virus, in this case the coronavirus, which causes COVID-19 - is killed or modified in such a way that it is unable to replicate.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          January 19, 2023

                          Lead Product(s) : mRNA-based COVID-19 Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Tru Niagen®, featuring Niagen®, is one of the top-selling brands in the Vitamin B3 category on Amazon U.S. for boosting NAD+ levels. Supplementation with Niagen® is backed by 20 published and peer-reviewed clinical trials.

                          Brand Name : Tru Niagen

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 10, 2022

                          Lead Product(s) : Nicotinamide Riboside

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Approved

                          Sponsor : ChromaDex, Inc

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The partnership will accelerate stockpiling, channel distribution and regional access of the amubarvimab/romlusevimab combination. Amubarvimab and Romlusevimab are non-competing SARS-CoV-2 monoclonal neutralizing antibodies derived from convalesced COVID...

                          Brand Name : BRII-196

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          March 30, 2022

                          Lead Product(s) : Amubarvimab,Romlusevimab

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Recipient : Brii Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          04

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : BBIBP-CorV vaccine is an inactivated SARS-CoV-2 vaccine (Vero cell), indicated the potential of BBIBP-CorV to provide cross-protection against other SARS-CoV-2 strains.

                          Brand Name : BBIBP-CorV

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          September 17, 2021

                          Lead Product(s) : Inactivated SARS-CoV-2 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : The inactivated COVID-19 vaccine developed by Beijing Institute of Biological Products of Sinopharm CNBG has been granted conditional registration by the NMPA of China, Chinese equivalent of FDA.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          January 02, 2021

                          Lead Product(s) : Inactivated Covid-19 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : MOHAP, in collaboration with Department of Health Abu Dhabi, DOH, has reviewed Sinopharm CNBG’s interim analysis of the phase III trials, which shows Beijing Institute of Biological Product’s inactivated vaccine to have 86 percent efficacy against CO...

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          December 09, 2020

                          Lead Product(s) : Inactivated Covid-19 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Approved

                          Sponsor : Beijing Institute of Biological Product

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Sinopharm's Vero cell is under Phase III randomized, double blind trial to evaluate the protective efficacy, safety and immunogenicity of inactivated SARS-CoV-2 Vaccines in healthy population aged 18 years old and above.

                          Brand Name : Vero cell

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          November 11, 2020

                          Lead Product(s) : Inactivated SARS-CoV-2 Vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Shanghai Fosun Pharmaceutical has signed a strategic cooperation agreement with Sinopharm Group to supply a coronavirus vaccine candidate developed by German firm BioNTech.

                          Brand Name : BNT162

                          Molecule Type : Vaccine

                          Upfront Cash : Undisclosed

                          September 07, 2020

                          Lead Product(s) : BNT162

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Fosun Pharmaceutical

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          09

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Sinopharm's inactivated COVID-19 vaccine had a low rate of adverse reactions and demonstrated immunogenicity, but longer-term assessment of safety and efficacy will require phase 3 trials.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          August 13, 2020

                          Lead Product(s) : Inactivated Covid-19 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Sinopharm has begun Phase III clinical trials of a COVID-19 vaccine in Bahrain, after launching similar trials in the United Arab Emirates last month.

                          Brand Name : Undisclosed

                          Molecule Type : Vaccine

                          Upfront Cash : Not Applicable

                          August 10, 2020

                          Lead Product(s) : COVID-19 vaccine

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank